In addition, a BTRS model derived from the C4 <i>BCL2L1<sup>+</sup></i> TCs subtype effectively stratified patient prognosis, as the high-risk group exhibited elevated expression of immune escape-related genes and impaired immune function.<h4>Conclusion</h4>This study revealed that the C4 <i>BCL2L1<sup>+</sup></i> TCs subtype might drive CRC progression by promoting metabolic adaptation and immune evasion. The gene discussed is BCL2L1; the disease is colorectal carcinoma.